B6.Cg-B2mtm1Unc H2-Ab1tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl

Status

Available to order

EMMA IDEM:05777
International strain nameB6.Cg-B2mtm1Unc H2-Ab1tm1Doi Tg(HLA-A/H2-D/B2M)1Bpe Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma Tg(MMTV-neu/OT-I/OT-II)CBnel/Orl
Alternative nameSURE-L1/Her2-neu
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolB2mtm1Unc,
Gene/Transgene symbolB2m

Information from provider

ProviderYu Chun LONE
Provider affiliationINSERM U1014
Genetic informationHLA-A2+/+, HLA-DR1+/+, Her2-neu+/+, IAbeta°, b2m°
Phenotypic informationHLA-A2+, HLA-DR1+, Her2-neu+, IAbeta°, b2m°
Breeding historyCofounder strain: B6.FVB-Tg Her2-neu, N10 C57BL/6 Cofounder strain (SURE-L1): HLA-A2/HLA-DR1/IAbeta°/ b2m°, N6 C57BL/6
References
  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
  • Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.;Wall Erika M, Milne Katy, Martin Michele L, Watson Peter H, Theiss Patty, Nelson Brad H, ;2007;Cancer research;67;6442-50; 17616705
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredyes
Immunocompromisedyes

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivinghomozygous 0, homozygous 0
Breeding at archiving centreHeterozygous knock-out for B2m (beta2m); homozygous knock-out for H2-Ab1 (AbetaA); transgenic for Tg(HLA-A/H2-D/B2M)1Bpe (HLAA2), Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dma (HLADRA1) and Tg(MMTV-neu/OT-I/OT-II)CBnel (Her2-neu).

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

MGI phenotypes (allele matching)
  • decreased level of surface class I molecules / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased IgG level / MGI
  • abnormal pancreas morphology / MGI
  • decreased susceptibility to bacterial infection / MGI
  • increased IgM level / MGI
  • decreased susceptibility to autoimmune diabetes / MGI
  • decreased circulating serum albumin level / MGI
  • increased T-helper 1 cell number / MGI
  • abnormal interleukin level / MGI
  • abnormal tumor necrosis factor level / MGI
  • increased susceptibility to infection induced morbidity/mortality / MGI
  • absent CD8-positive, alpha-beta T cells / MGI
  • abnormal pancreatic beta cell morphology / MGI
  • abnormal T cell number / MGI
  • insulitis / MGI
  • abnormal neuron proliferation / MGI
  • abnormal immune system morphology / MGI
  • abnormal spleen morphology / MGI
  • abnormal immune system cell morphology / MGI
  • postnatal growth retardation / MGI
  • abnormal immune system physiology / MGI
  • reduced fertility / MGI
  • abnormal spleen periarteriolar lymphoid sheath morphology / MGI
  • abnormal spleen marginal zone morphology / MGI
  • abnormal CD4-positive, alpha beta T cell morphology / MGI
  • abnormal T cell physiology / MGI
  • abnormal B cell physiology / MGI
  • abnormal immune system organ morphology / MGI
  • abnormal cytokine secretion / MGI
  • decreased susceptibility to parasitic infection / MGI
  • increased susceptibility to parasitic infection / MGI
  • abnormal CD4-positive, alpha-beta T cell physiology / MGI
  • increased CD4-positive, alpha beta T cell number / MGI
  • decreased CD4-positive, alpha beta T cell number / MGI
  • increased CD8-positive, alpha-beta T cell number / MGI
  • abnormal spleen B cell follicle morphology / MGI
  • absent spleen germinal center / MGI
  • decreased IgG1 level / MGI
  • abnormal lymph node cell ratio / MGI

Literature references

  • A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice.;Pajot Anthony, Michel Marie-Louise, Fazilleau Nicolas, Pancré Véronique, Auriault Claude, Ojcius David M, Lemonnier François A, Lone Yu-Chun, ;2004;European journal of immunology;34;3060-9; 15468058
  • Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells.;Wall Erika M, Milne Katy, Martin Michele L, Watson Peter H, Theiss Patty, Nelson Brad H, ;2007;Cancer research;67;6442-50; 17616705

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).